We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Insights into Blood Diseases from Worms and Mice

By Biotechdaily staff writers
Posted on 23 May 2002
Results from genetic studies on microscopic worms extrapolated to a mouse model have revealed comparable genes that control early blood-cell development.

"We think we have found a way of efficiently studying how early blood-cell development is controlled and how gene defects in this process might lead to the development of blood diseases, including cancer,” said Dr. More...
Scott Cameron, an assistant professor of pediatrics and molecular biology at the University of Texas Southwestern Medical Center (Dallas, USA).

The research was reported in the February 1, 2002, issue of Genes & Development (mouse study) and in the April 1, 2002, issue of Development (worm study). Dr. Cameron and colleagues from Harvard Medical School (Boston, MA, USA; www.med.harvard.edu) found that the pag-3 gene determines the fate of embryonic nerve cells in the microscopic worm Caenorhabditis elegans, a common soil nematode that was one of the first animals to have its genome sequenced. Worms with a mutation on the pag-3 gene did not develop the neuron cells that control forward and backward mobility.

"In the gene-deprived mice, I found a defect in blood formation exactly consistent with what was predicted by the worm work,” said Dr. Cameron. The mouse study revealed that when the Gfi-1b gene is muted in mice, their blood-stem cells fail to form red cells and platelets, causing mice embryos to die 11-12 days after fertilization. Related research has shown that knocking out the sister Gfi-1 gene prevents development of certain white blood cells, resulting in the mice dying shortly after birth. The blood-cell genetic defects in the mice were consistent with the defect identified in embryonic nerve cells in C elegans.

Dr. Cameron hopes to find comparable links to cancer tumors in humans, though he cautions that gene numbers, roles, mutations and other variants contrast sharply between the mouse and human genomes and raise major challenges for human-disease research. "But I know that, overall, I'm in the right genetic neighborhood,” he said.





Related Links:
Southwestern Medical Center
Harvard Medical School

Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
POCT Fluorescent Immunoassay Analyzer
FIA Go
Gold Member
Automated Staining Unit
RAL Stainer
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.